Can Corticosteroids Be Injected Into Hoffa's Fat Pad?
Yes, corticosteroid injections into the infrapatellar fat pad (Hoffa's fat pad) can be performed and have been used clinically, though recent high-quality evidence shows limited efficacy for inflammatory knee osteoarthritis.
Evidence-Based Assessment
The most recent and highest quality study addressing this specific question is a 2026 randomized controlled trial published in JAMA Network Open 1. This double-blind, placebo-controlled trial evaluated ultrasound-guided glucocorticoid injections directly into the IPFP in 60 patients with inflammatory knee osteoarthritis. The trial found that glucocorticoid injections into the IPFP did not significantly reduce knee pain on VAS (-39.3 mm vs -31.4 mm in placebo; between-group difference -7.9 mm) or effusion synovitis volume compared to placebo 1. However, post hoc analyses showed potential benefits in WOMAC pain scores and cartilage defect reduction 1.
Technical Feasibility and Safety
From a technical standpoint, injecting corticosteroids into Hoffa's fat pad is feasible:
- Ultrasound guidance is recommended for accurate needle placement into the IPFP 1, 2
- The procedure has been successfully performed in clinical trials with minimal adverse events (only 1 adverse reaction in each group in the JAMA trial) 1
- Historical literature describes injections through the patellar tendon, though this approach carries risks of inadvertent fat pad or ACL injection 3
Clinical Context and Indications
The rationale for targeting the IPFP stems from its role as a source of inflammation in knee OA 1, 4. The fat pad is richly innervated and vascularized, making it a potential pain generator 4. Specific scenarios where IPFP injection has been explored include:
- Hoffa's disease (inflammation/fibrosis of the fat pad) 4
- Ganglion cysts arising from Hoffa's fat pad - successfully treated with ultrasound-guided steroid injection in case reports 2
- Inflammatory knee OA phenotype with both Hoffa-synovitis and effusion-synovitis 1, 5
Comparison to Standard Intra-Articular Injection
Standard intra-articular glucocorticoid injection remains the evidence-based approach for knee OA exacerbations 6. The 2021 EULAR guidelines recommend intra-articular injection of long-acting glucocorticoids for acute exacerbation of knee pain, especially with effusion 6. These guidelines do not specifically address IPFP injection as a distinct technique.
The theoretical advantage of IPFP injection over standard intra-articular injection is targeting the inflammatory source while potentially avoiding cartilage exposure to corticosteroids, which may cause cartilage loss with repeated use 1. However, the 2026 JAMA trial failed to demonstrate superior clinical efficacy for this targeted approach 1.
Practical Recommendations
For routine clinical practice, standard intra-articular glucocorticoid injection following EULAR guidelines should be preferred over IPFP-specific injection 6. The IPFP injection approach lacks sufficient evidence of superiority and requires specialized ultrasound guidance.
Consider IPFP-targeted injection only in specific circumstances:
- Documented Hoffa's disease or IPFP pathology on imaging 4
- IPFP ganglion cysts 2
- Research protocols or specialized centers with ultrasound expertise 1
Important Caveats
- Shared decision-making is essential - patients should be informed about limited evidence for IPFP-specific injection 6
- Avoid joint overuse for 24 hours following any intra-articular therapy, though immobilization is discouraged 6
- Monitor glucose levels in diabetic patients, particularly days 1-3 post-injection 6
- The procedure should be performed under ultrasound guidance to ensure accurate needle placement 1, 2
- Diagnosis should be confirmed before injection - inappropriate use without proper diagnosis is contraindicated 6